Epigenomics is a Berlin-based startup that focuses on developing and manufacturing a pipeline of products for the diagnosis of cancer. Epigenomics’ mission is to develop diagnostic tests that can detect cancer at early stages before symptoms occur, conveniently carried out on body fluids such as blood plasma. In this startup showcase, we delve into the innovations that make Epigenomics stand out in the industry.
Molecular Diagnostics
Epigenomics is a molecular diagnostics company that focuses on the development and commercialization of in vitro diagnostic tests for cancer. The company’s cancer diagnostic tests aim to find cancer at early stages, potentially addressing millions of individuals in major markets such as the United States, Europe, and Japan. The company’s tests provide product opportunities with peak sales potentials of several hundred million euros for diagnostics companies worldwide.
Lead Test Development Program
Epigenomics’ lead test development program is in colorectal cancer, and the company has several other tests in development for lung and prostate cancer. Each of its products in development addresses either mass markets or high-value niches. Some of these products lend themselves to partnering with established diagnostics industry players, while others can be commercialized effectively by Epigenomics itself.
DNA Methylation Patterns
The concept of Epigenomics’ diagnostic tests relies on detecting differences in DNA methylation patterns between healthy and sick individuals or between subgroups of patients for disease classification. This approach enables Epigenomics to provide highly accurate and reliable diagnostic tests that can detect cancer at early stages, allowing for timely intervention and treatment.
Conclusion
Epigenomics is an innovative startup that focuses on developing and manufacturing diagnostic tests for cancer using molecular diagnostics. By detecting differences in DNA methylation patterns, Epigenomics’ tests can detect cancer at early stages, potentially saving millions of lives. With its lead test development program in colorectal cancer and other tests in development for lung and prostate cancer, Epigenomics is well-positioned to make a significant impact in the cancer diagnostics industry.
Website: http://epigenomics.com
Twitter: http://twitter.com/EpigenomicsInc
Facebook: https://www.facebook.com/epigenomics/
LinkedIn: https://www.linkedin.com/company/epigenomics-ag/
Want to amplify your startup’s story? EU Startup News is your launchpad to reach startup founders, investors, and C-level execs across Europe. Discover our tailored promotional strategies such as Sponsored Articles and Partnerships. Click here to learn more or contact us directly at [email protected]. Join us, and let’s make your startup the talk of Europe!
